Target identification and validation for anthelmintic discovery

Expert Opinion on Drug Discovery

Volumn 2, Issue SUPPL. 1, 2007, Pages

  Grant, Warwick N ^a   Behm, Carolyn A ^b  

^a LA TROBE UNIVERSITY   (Australia)

^b AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

Author keywords

Anthelmintic; Drug target; Functional genomics; Helminth; RNAi; Target validation

Indexed keywords

ANTHELMINTIC AGENT; AVERMECTIN; BENZIMIDAZOLE DERIVATIVE; CLOSANTEL; DIETHYLCARBAMAZINE; HELMINTH DNA; LEVAMISOLE; MACROLIDE; PRAZIQUANTEL; PYRANTEL;

ARTICLE; BIOINFORMATICS; CAENORHABDITIS ELEGANS; CLINICAL EFFECTIVENESS; DNA SEQUENCE; DRUG BINDING; DRUG DETERMINATION; DRUG RESEARCH; DRUG SPECIFICITY; FUNCTIONAL GENOMICS; GENE IDENTIFICATION; HELMINTHIASIS; HIGH THROUGHPUT SCREENING; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; RNA INTERFERENCE; SEQUENCE ANALYSIS; VALIDATION STUDY;

EID: 35348991523     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.2.S1.S91     Document Type: Article

References (50)

1. PINK R, HUDSON A, MOURIES MA, BENDIG M: Opportunities and challenges in antiparasitic drug discovery. Nat. Rev. Drug Discov. (2005) 4(9):727-740.
2. OMURA S, CRUMP A: The life and times of ivermectin - a success story. Nat. Rev. Microbiol. (2004) 2(12):984-989.
3. CULLY DF, VASSILATIS DK, LIU KK et al.: Cloning of an avermectin-sensitive glutamate-gated chloride channel from Caenorhabditis elegans. Nature (1994) 371(6499):707-711.
4. WOLSTENHOLME AJ, FAIRWEATHER I, PRICHARD R, VON SAMSON-HIMMELSTJERNA G, SANGSTER NC: Drug resistance in veterinary helminths. Trends Parasitol. (2004) 20(10):469-476.
5. ALTREUTHER G, BUCH J, CHARLES SD et al.: Field evaluation of the efficacy and safety of emodepside/praziquantel spot-on solution against naturally acquired nematode and cestode infections in domestic cats. Parasitol. Res. (2005) 97(Suppl. 1):S58-S64.
6. HARDER A, VON SAMSON-HIMMELSTJERNA G: Activity of the cyclic depsipeptide emodepside (BAY 44-4400) against larval and adult stages of nematodes in rodents and the influence on worm survival. Parasitol. Res. (2001) 87(11):924-928.
7. OVERINGTON JP, AL-LAZIKANI B, HOPKINS AL: How many drug targets are there? Nat. Rev. Drug Discov. (2006) 5(12):993-996.
8. WILLSON J, AMLIWALA K, HARDER A, HOLDEN-DYE L, WALKER RJ: The effect of the anthelmintic emodepside at the neuromuscular junction of the parasitic nematode Ascaris suum. Parasitology (2003) 126(Part 1):79-86.
9. BECKER D, SELBACH M, ROLLENHAGEN C et al.: Robust Salmonella metabolism limits possibilities for new antimicrobials. Nature (2006) 440(7082):303-307.
10. MCCARTER JP: Genomic filtering: an approach to discovering novel antiparasitics. Trends Parasitol. (2004) 20(10):462-468.
11. BEHM CA, BENDIG MM, MCCARTER JP, SLUDER AE: RNAi-based discovery and validation of new drug targets in filarial nematodes. Trends Parasitol. (2005) 21(3):97-100.
12. JONES AK, BUCKINGHAM SD, SATTELLE DB: Chemistry-to-genes screens in Caenorhabditis elegans. Nat. Rev. Drug Discov. (2005) 4(4):321-330.
13. KWOK TC, RICKER N, FRASER R et al.: A small-molecule screen in C. elegans yields a new calcium channel antagonist. Nature (2006) 441(7089):91-95.
14. GELDHOF P, MOLLOY C, KNOX DP: Combinatorial RNAi on intestinal cathepsin B-like proteinases in Caenorhabditis elegans questions the perception of their role in nematode biology. Mol. Biochem. Parasitol. (2006) 145(1):128-132.
15. ZAWADZKI JL, PRESIDENTE PJ, MEEUSEN EN, DE VEER MJ: RNAi in Haemonchus contortus: a potential method for target validation. Trends Parasitol. (2006) 22(11):495-499.
16. KNOX DP, GELDHOF P, VISSER A, BRITTON C: RNA interference in parasitic nematodes of animals: a reality check? Trends Parasitol. (2007) 23(3):105-107.
17. GELDHOF P, VISSER A, CLARK D et al.: RNA interference in parasitic helminths: current situation, potential pitfalls and future prospects. Parasitology (2007):1-11.
18. ABOOBAKER AA, BLAXTER ML: Use of RNA interference to investigate gene function in the human filarial nematode parasite Brugia malayi. Mol. Biochem. Parasitol. (2003) 129(1):41-51.
19. ISSA Z, GRANT WN, STASIUK S, SHOEMAKER CB: Development of methods for RNA interference in the sheep gastrointestinal parasite, Trichostrongylus colubriformis. Int. J. Parasitol. (2005) 35(9):935-940.
20. GELDHOF P, MURRAY L, COUTHIER A et al.: Testing the efficacy of RNA interference in Haemonchus contortus. Int. J. Parasitol. (2006) 36(7):801-810.
21. LUSTIGMAN S, ZHANG J, LIU J, OKSOV Y, HASHMI S: RNA interference targeting cathepsin L and Z-like cysteine proteases of Onchocerca volvulus confirmed their essential function during L3 molting. Mol. Biochem. Parasitol. (2004) 138(2):165-170.
22. KAMATH RS, FRASER AG, DONG Y et al.: Systematic functional analysis of the Caenorhabditis elegans genome using RNAi. Nature (2003) 421(6920):231-237.
23. SIMMER F, MOORMAN C, VAN DER LINDEN AM et al.: Genome-wide RNAi of C. elegans using the hypersensitive rrf-3 strain reveals novel gene functions. PLoS Biol. (2003) 1(1):77-84.
24. SKELLY PJ, DA'DARA A, HARN DA: Suppression of cathepsin B expression in Schistosoma mansoni by RNA interference. Int. J. Parasitol. (2003) 33(4):363-369.
25. BOYLE JP, WU XJ, SHOEMAKER CB, YOSHINO TP: Using RNA interference to manipulate endogenous gene expression in Schistosoma mansoni sporocysts. Mol. Biochem. Parasitol. (2003) 128(2):205-215.
26. SANCHEZ ALVARADO A, NEWMARK PA: Double-stranded RNA specifically disrupts gene expression during planarian regeneration. Proc. Natl. Acad. Sci. USA (1999) 96(9):5049-5054.
27. REDDIEN PW, BERMANGE AL, MURFITT KJ, JENNINGS JR, SANCHEZ ALVARADO A: Identification of genes needed for regeneration, stem cell function, and tissue homeostasis by systematic gene perturbation in planaria. Dev. Cell (2005) 8(5):635-649.
28. BRYANT C, BEHM CA: Biochemical Adaptation in Parasites. (Ed.), Chapman and Hall, London (1989):259.
29. BEHM CA: Metabolism. In: The Biology of Nematodes. Lee DL (Ed.), Taylor & Francis, London (2002):261-290.
30. ROOS DS: The apicoplast as a potential therapeutic target in toxoplasma and other apicomplexan parasites: some additional thoughts. Parasitol. Today (1999) 15(1):41.
31. PARKINSON J, MITREVA M, HALL N, BLAXTER M, MCCARTER JP: 400000 nematode ESTs on the Net. Trends Parasitol. (2003) 19(7):283-286.
32. PARKINSON J, MITREVA M, WHITTON C et al.: A transcriptomic analysis of the phylum nematoda. Nat. Genet. (2004) 36(12):1259-1267.
33. BARRETT J: Biochemistry of Parasitic Helminths. (Ed.), MacMillan, London, (1981):308.
34. BARRETT J: Biochemistry of filarial worms. Helminthological Abstracts (1983) A52:1-18.
35. BARRETT J: Amino acid metabolism in helminths. Adv. Parasitol. (1991) 30:39-105.
36. BARRETT J: Helminth detoxification mechanisms. J. Helminthol. (1997) 71(2):85-89.
37. BARRETT J, WRIGHT DJ: Intermediary metabolism. In: The Physiology and Biochemistry of Free-Living and Plant-Parasitic Nematodes. Perry RN et al. (Eds), CAB International, Wallingford (1998):331-353.
38. VAN GILST M, GISSENDANNER CR, SLUDER AE: Diversity and function of orphan nuclear receptors in nematodes. Crit. Rev. Eukaryot. Gene Expr. (2002) 12(1):65-88.
39. KELLER TH, PICHOTA A, YIN Z: A practical view of 'druggability'. Curr. Opin. Chem. Biol. (2006) 10(4):357-361.
40. LIPINSKI CA, LOMBARDO F, DOMINY BW, FEENEY PJ: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. (2001) 46(1-3):3-26.
41. LIPINSKI C, HOPKINS A: Navigating chemical space for biology and medicine. Nature (2004) 432(7019):855-861.
42. HOPKINS AL, GROOM CR: The druggable genome. Nat. Rev. Drug Discov. (2002) 1(9):727-730.
43. RUSSELL GJ, GILL JH, LACEY E: Binding of [3H]benzimidazole carbamates to mammalian brain tubulin and the mechanism of selective toxicity of the benzimidazole anthelmintics. Biochem. Pharmacol. (1992) 43(5):1095-1100.
44. GILL JH, LACEY E: The kinetics of mebendazole binding to Haemonchus contortus tubulin. Int. J. Parasitol. (1992) 22(7):939-946.
45. MARTIN RJ, VERMA S, LEVANDOSKI M et al.: Drug resistance and neurotransmitter receptors of nematodes: recent studies on the mode of action of levamisole. Parasitology (2005) 131 (Suppl.):S71-S84.
46. SCHINKEL AH, SMIT JJ, VAN TELLINGEN O et al.: Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell (1994) 77(4):491-502.
47. THOMPSON FJ, BARKER CL, HUGHES L et al.: A microarray analysis of gene expression in the free-living stages of the parasitic nematode Strongyloides ratti. BMC Genomics (2006) 7:157.
48. LOCHNIT G, BONGAARTS R, GEYER R: Searching new targets for anthelminthic strategies: interference with glycosphingolipid biosynthesis and phosphorylcholine metabolism affects development of Caenorhabditis elegans. Int. J. Parasitol. (2005) 35:911-923.
49. PULAK R: Techniques for analysis, sorting, and dispensing of C. elegans on the COPAS flow-sorting system. Methods Mol. Biol. (2006) 351:275-286.
50. PAYNE DJ, GWYNN MN, HOLMES DJ, POMPLIANO DL: Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. (2007) 6(1):29-40.